<div id="readability-page-1"><div id="article-body-row"> <div> Most biopharma brands have more approved content than ever before. Yet HCP and patient engagement haven’t kept pace.The data makes it clear that the biopharma digital experience is failing HCPs and patients alike. 58% of HCPs find digital content repetitive or irrelevant. And 76% of patients feel frustrated when they do not find the personalized experience they expect.The problem, of course, is not a lack of approved content. It’s access. In practice, omnichannel marketing has largely seen organizations push the same content across different channels, thereby placing the burden on HCPs and patients to hunt for what they need while wading through repetitive content. There’s no intelligence behind it, only distribution.AI offers an opportunity to actually address this problem. It can understand what someone is looking for and surface the right response immediately, without forcing the HCP or patient to navigate a static site or wait for a rep to reach out.But in biopharma, the stakes of getting AI wrong are high. A 2026 study found that medical responses were problematic in up to 43% of answers. In a highly regulated industry, that kind of variability poses serious compliance and patient safety issues. Inaccurate claims, off-label messaging and outdated information erode trust. In the worst cases, they can directly impact patient health.Compliant AI makes a difference by surfacing approved content rather than generating new answers. Every single response traces back to PRC-approved content to ensure compliance and safety for HCPs, patients, and brands.Compliant AI for omnichannel in practiceVeeva Ostro is built on this exact architecture. It transforms brand.com into a conversational AI experience where HCPs and patients ask questions in natural language and get instant, PRC-approved answers. Brand sites are typically where the experience starts, but not where it ends. When an HCP visits a brand site and asks a clinical question, the interaction becomes a signal. When an HCP can later reply to a brand email to surface the co-pay card for their patient. Or receive an answer about the drug's side effects, all without requiring them to return to and navigate brand.com, the engagement is fundamentally different and improved. No longer tethered to the website, each channel draws from the same PRC-approved content library, so the experience stays compliant and connected regardless of where the conversation happened.One global oncology brand deployed Ostro’s solution on its HCP site for a therapy with multiple indications. HCPs could ask for indication-specific dosing guidance in plain language and get it immediately. Similarly, a dynamic “Contact a Rep” form surfaced when HCPs showed intent to engage. The result: HCPs were 36 times more likely to complete that form. That lift didn't come from more traffic; it came from removing the friction between question and answer.Intelligence emerges from engagement Every interaction across channels provides signals: What HCPs and patients seek, where content falls short and which HCPs are close to engaging with a rep. Ostro captures it all and feeds it back to brand teams and field reps.Let’s say an HCP is searching for dosing information between patients. If she asks that question on a brand site running Ostro, the brand team learns that the dosing section isn't answering what HCPs are actually asking. Before picking up a phone, the rep learns that the HCP was on the site and what she was looking for. The next conversation starts from a different, and more informed, place.That's precisely the feedback loop omnichannel has always needed: Not just getting content in front of patients and HCPs, but knowing what they're asking, filling the gaps and connecting every digital interaction back to brand teams who can take action.The brands that succeed in omnichannel won’t be the ones that push the most content. Instead, they will be the ones that solve the access problem with compliant AI that connects HCPs and patients to the right answers, on any channel, right when they need it. Click here to see how Veeva Ostro makes this possible. </div> </div></div>

VEEV

SBIO

LABU

LABD

The biopharma industry faces challenges in HCP and patient engagement despite having more approved content. A significant percentage of HCPs find digital content repetitive, while many patients feel frustrated by the lack of personalized experiences. The issue lies in access, as omnichannel marketing often fails to provide intelligent content distribution. Compliant AI, like Veeva Ostro, addresses this by delivering PRC-approved responses in real-time, enhancing engagement and ensuring compliance. Successful brands will leverage AI to connect HCPs and patients with the right information across channels, improving overall digital experiences.

Omnichannel Has an Access Problem. Compliant AI Fixes It.